.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Queensland Health
Merck
Boehringer Ingelheim
Cipla
Novartis
Accenture
Teva
Federal Trade Commission

Generated: November 20, 2017

DrugPatentWatch Database Preview

Teva Pharms Intl Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS INTL, and when can generic versions of TEVA PHARMS INTL drugs launch?

TEVA PHARMS INTL has two approved drugs.

There are nine US patents protecting TEVA PHARMS INTL drugs on TEVA PHARMS INTL drugs in the past three years.

There are forty-four patent family members on TEVA PHARMS INTL drugs in nineteen countries.

Summary for Teva Pharms Intl

International Patents:44
US Patents:9
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Intl
SYNRIBO
omacetaxine mepesuccinate
POWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► Subscribe ► Subscribe
Teva Pharms Intl
SYNRIBO
omacetaxine mepesuccinate
POWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Teva Pharms Intl
SYNRIBO
omacetaxine mepesuccinate
POWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-002Feb 1, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Teva Pharms Intl
SYNRIBO
omacetaxine mepesuccinate
POWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-002Feb 1, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TEVA PHARMS INTL drugs

Drugname Dosage Strength Tradename Submissiondate
omacetaxine mepesuccinate
for Injection3.5 mg/vial
SYNRIBO
10/26/2016
cyclobenzaprine hydrochloride
Extended-release Capsule15 mg and 30 mg
AMRIX
8/11/2008

Non-Orange Book Patents for Teva Pharms Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,877,245Modified release dosage forms of skeletal muscle relaxants► Subscribe
6,613,900 Cephalotaxane derivatives and process for their preparation► Subscribe
6,831,180 Cephalotaxane derivatives and process for their preparation► Subscribe
7,842,687Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
7,169,774Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Teva Pharms Intl Drugs

Country Document Number Estimated Expiration
Japan4794816► Subscribe
Portugal2177223► Subscribe
Japan2015117251► Subscribe
France2776292► Subscribe
Japan2009102408► Subscribe
Australia2002337410► Subscribe
Denmark1064285► Subscribe
Hungary0101375► Subscribe
European Patent Office1373275► Subscribe
Hong Kong1143732► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
McKesson
Fuji
Citi
Dow
Farmers Insurance
Mallinckrodt
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot